Prospective noninterventional study on peripheral blood stem cell mobilization in patients with relapsed lymphomas

Gwendolyn van Gorkom*, Herve Finel, Sebastian Giebel, David Pohlreich, Avichai Shimoni, Mark Ringhoffer, Gulsan Sucak, Nicolaas Schaap, Peter Dreger, Anna Sureda, Harry C. Schouten

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

6 Citations (Web of Science)

Abstract

High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) to rescue hematopoiesis is considered standard care for patients with a relapsed chemosensitive lymphoma, but diagnosis of lymphoma has been a risk factor for poor mobilization in several studies. The aim of this prospective noninterventional clinical audit was to review the mobilization strategies used by EBMT centers in relapsed lymphoma and to evaluate their efficacy. Between 2010 and 2014, 275 patients with relapsed lymphoma from 30 EBMT centers were prospectively registered. Almost all patients were mobilized with chemotherapy plus G-CSF (96%), but there was a large variation in chemotherapy schedules. Thirty (11%) of them were poor mobilizers (

Original languageEnglish
Pages (from-to)295-301
Number of pages7
JournalJournal of Clinical Apheresis
Volume32
Issue number5
DOIs
Publication statusPublished - Oct 2017

Keywords

  • relapsed lymphomas
  • stem cell mobilization
  • BONE-MARROW-TRANSPLANTATION
  • NON-HODGKINS-LYMPHOMA
  • POOR MOBILIZATION
  • RISK-FACTORS
  • CHEMOTHERAPY
  • FILGRASTIM
  • TRIAL

Cite this